Form D · Biotechnology
Skye Bioscience, Inc.
San Diego, CA · CIK 0001516551
Offering snapshot reported Mar 27, 2024 · SEC filing
- Reported sold
- $40M Offering amount: $40M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 13, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2024 | Initial | $40,000,000 | No comparison | 13 | SEC filing |
| Feb 12, 2024 | Initial | $49,991,010 | No comparison | 11 | SEC filing |
| Aug 29, 2023 | Initial | $62,254,435 | No comparison | 12 | SEC filing |
| Nov 15, 2018 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Feb 23, 2018 | Amendment | $4,150,000 | $1,750,000vs Jan 25, 2018 | 2 | SEC filing |
| Jan 25, 2018 | Initial | $2,400,000 | No comparison | 1 | SEC filing |
| Nov 14, 2017 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
| Jan 13, 2017 | Initial | $1,200,000 | No comparison | 5 | SEC filing |
| Nov 3, 2016 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Aug 27, 2015 | Initial | $5,000,000 | No comparison | 15 | SEC filing |
| Apr 15, 2015 | Initial | $625,000 | No comparison | 5 | SEC filing |
| Jan 9, 2015 | Initial | $724,989 | No comparison | 7 | SEC filing |
| Nov 13, 2014 | Initial | $0 | No comparison | 43 | SEC filing |
| Jan 22, 2013 | Amendment | $24,800 | No comparison | 13 | SEC filing |
| Nov 8, 2012 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 7, 2012 | Amendment | $9,000 | No comparison | 7 | SEC filing |
| Mar 25, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.4M
- Finders' fees
- $0
- Form D file number
- 021-508708
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Piper Sandler & Co | 665 | |
| Oppenheimer & Co. Inc. | 249 |
Source: Form D, filed Mar 27, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kaitlyn Arsenault | Executive |
| Elizabeth M. Berecz | Executive |
| Douglas A. Cesario | Executive |
| Deborah Charych | Director |
| Margaret Dalesandro | Director |
| Avtar Dhillon | Director |
| Punit Dhillon | Director, Executive |
| Thomas A. George | Director |
| Paul Grayson | Director |
| Jim Heppell | Director |
| James L. Heppell | Director |
| John B. Hollister | Director, Executive |
| Douglas S. Ingram | Director |
| Annalisa Jenkins | Director |
| Cosmas N. Lykos | Director, Executive |
| Gerald W. Mc Laughlin | Director |
| Francicso Mendez | Promoter |
| Francisco J. Mendez | Director, Executive, Promoter |
| Yosbani Mendez | Promoter |
| Brian S. Murphy | Director, Executive |
| Andrew Schwab | Director |
| Praveen Tyle | Director |
| Keith Ward | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11250 El Camino Real, Suite 100
San Diego, CA, 92130
San Diego, CA, 92130